



Cancer-Therapy-Related Adverse Events

Guest Editors:

Dr. Yinghong Wang

Department of Gastroenterology,
Hepatology and Nutrition, The
University of Texas MD Anderson
Cancer Center, Houston, TX
77030, USA

Dr. Pauline Funchain

The Stanford Cancer Institute,
Stanford University, Stanford, CA
94305, USA

Deadline for manuscript
submissions:

closed (31 March 2025)

Message from the Guest Editors

With new cancer treatment strategies emerging rapidly, we recognize the limitations and the need for expanding upon our knowledge of toxicity management. These hurdles frequently disrupt cancer treatments and compromise patients' outcomes. There is a critical knowledge gap in current clinical practices that needs to be bridged by research data to help practitioners and patients improve their quality of care and outcome.

This Special Issue aims to cover the various organ toxicities related to cancer therapies in the current era. This Special Issue will help to facilitate optimization in the clinical management of cancer care and to reduce symptom burden due to adverse events for cancer populations.

Original research articles and reviews are welcome in this Special Issue. Research areas may include (but are not limited to) cancer-therapy-related adverse events in different organs from one or more of the following categories.

- Toxicity topic
- Cardiology
- Dermatology
- Endocrinology
- Gastroenterology
- Hematology
- Hepatology
- Nephrology
- Neurology
- Ophthalmology
- Pancreatology





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)